Companies: 10,795·Total market cap: $144.5T
Adaptive Biotechnologies Corporation

Adaptive Biotechnologies Corporation

ADPTNASDAQHealthcare● Active
$16.84
$-0.06(-0.34%)
Market Cap$2.7B
P/E Ratio
52W High$20.76
52W Low$9.78

Adaptive Biotechnologies Corporation (ADPT) Stock Forecast & Analyst Price Target

Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.

adpt · stock forecast · 17 analysts (3M) · FMP · updated Jun 8, 2026

Analyst Rating & Consensus

Based on 17 Wall Street analysts in the past 3 months

SellBuy

Buy

17 analysts

consensus

Rating Breakdown

Strong Buy
0
Buy
11
Hold
4
Sell
2
Strong Sell
0
Total: 17 · Buy rate: 64.7%

12-Month Price Target

High

$22.00

Consensus

$21.33

+23.2% upside

Low

$21.00

Median: $21 · Last Close: $17.32

The Adaptive Biotechnologies Corporation (ADPT) analyst consensus is Buy, based on ratings from 17 Wall Street analysts over the past 3 months. The average 12-month ADPT price target is $21.33, representing +23.2% upside from the current price of $17.32.

12-Month Price Target Forecast

Historical closing prices + analyst 12-month price target forecast cone

Historical priceConsensus $21 (23.2%)

Consensus Target

$21.33

23.2% upside

High Target

$22

27.0%

Low Target

$21

21.2%

Current Price

$17.32

as of today

Based on analyst price targets, the ADPT stock price prediction for the next 12 months ranges from $21 to $22. The consensus ADPT price forecast of $21.33 implies 23.2% upside from the current price of $17.32.

Short-Term Price Prediction

Algorithmically generated · Updated daily

DatePredicted PriceChange
2026-06-09$18.195.00%

1-day model range: $18.04–$18.33. Peak: $18.33 (+5.00%).

Long-Term Stock Price Prediction

Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031

YearAvg PriceChange
2027$18+2.0%
2028$18+3.2%
2029$18+3.9%
2030$18+4.3%
2031+4.6%
Confidence:Medium

Stock Forecast Based on Technical Analysis

14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency

Market Sentiment

BULLISH

Based on 14 technical indicators

93%0%7%
13Buy
0Neutral
1Sell
RSI (14)78.8Overbought
MACDBULLISH

Refreshes daily from EOD close

Moving Averages · ADPT · Jun 8, 2026

Simple Moving Average (SMA)
MA 5$16.69BUY
MA 10$15.70BUY
MA 20$14.53BUY
MA 50$14.24BUY
MA 100$15.12BUY
MA 200$15.28BUY
Current $ADPT · Price above MA = BUY signal
Exponential Moving Average (EMA)
EMA 5$16.73BUY
EMA 10$15.96BUY
EMA 20$15.17BUY
EMA 50$14.67BUY
EMA 100$14.78BUY
EMA 200$14.26BUY
Current $ADPT · Price above MA = BUY signal
How we calculate: Technical sentiment is derived from 14 indicators — SMA(5,10,20,50,100,200), EMA(5,10,20,50,100,200), RSI(14), and MACD(12,26,9) — calculated from historical EOD price data. BUY = current price above MA; SELL = below. 14 TA signals + historical EOD price data · Updated daily. Independent of analyst consensus data. Not investment advice.

Latest Analyst Ratings & Upgrades

Filter:
Morgan Stanley2026-05-12
Maintains
Equal WeightEqual Weight
Guggenheim2026-05-06
Maintains
BuyBuy
TD Cowen2026-05-06
Maintains
BuyBuy
JP Morgan2026-05-06
Maintains
OverweightOverweight
BTIG2026-05-06
Maintains
BuyBuy
JP Morgan2026-02-06
Maintains
OverweightOverweight
BTIG2026-02-06
Maintains
BuyBuy
Guggenheim2026-01-26
Maintains
BuyBuy
Morgan Stanley2025-11-11
Maintains
Equal WeightEqual Weight
BTIG2025-11-06
Maintains
BuyBuy

Wall Street analysts have recently issued updated ratings on Adaptive Biotechnologies Corporation (ADPT) stock. Of the recent 81 rating actions, 4 were upgrades and 11 were downgrades. 17 analysts currently cover ADPT.

Analyst Recommendation Trends

Buy ratings34↑ +1
Hold ratings01↑ +1
Sell ratings00

ADPT analyst recommendation trends show increasing buy-side sentiment over the past 6 months. Buy rating actions changed from 3 to 4 per month.

Financial Forecast: EPS & Revenue Estimates

Revenue This Year

$286M

↓ 33.1% YoY

Revenue Next Year

$350M

↑ 22.4% YoY

EPS This Year

$-0.46

EPS Next Year

$-0.25

↓ 46.1% YoY

EPS ForecastReported vs Estimated

Reported EPSHistorical estimateAnalyst forecast (future)

Analysts forecast ADPT EPS of $-0.46 for the current fiscal year, based on estimates from 6 analysts. The ADPT revenue forecast is $286M for the current year. These are analyst consensus estimates via FMP / S&P Global.

About Forecast & Price Prediction

The ADPT stock forecast is supported by two independent data sources: analyst consensus ratings from 17 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus ADPT price target is $21.33 (+23.2% upside), with an analyst consensus of Buy.

The ADPT short-term stock prediction for tomorrow is $18.19 (+5.00%). The ADPT stock price prediction for 2027 estimates an average of $18. The ADPT stock prediction for 2030 projects a range of $16–$20.

Adaptive Biotechnologies Corporation trades on NASDAQ under the ticker ADPT. The ADPT stock outlook for 2027 is broadly positive, supported by a Buy consensus among 65% of covering analysts.

FAQ answers synthesize analyst targets, estimates, and on-page model outputs where shown.

Frequently asked questions

ADPT forecast · 8 questions

According to 17 Wall Street analysts, the average 12-month ADPT price target is $21.33, with a high forecast of $22.00 and a low of $21.00. The median price target is shown in the chart above when available. This implies +23.2% potential upside from the current price of $17.32.

ADPT price targetWhat is ADPT price targetADPT analyst price targetADPT 12-month target

· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)

⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.